Investigational drug · Phase 2
BL-M08D1
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Gastrointestinal Tumors, Diffuse Large B-Cell Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
8
Any phase or sponsor naming "BL-M08D1"
First trial start
2026
Sep 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BL-M08D1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Gastrointestinal Tumors
- Diffuse Large B-Cell Lymphoma
- Melanoma
- Nasopharyngeal Carcinoma (NPC)
- Gynecological Tumors
- Head and Neck Squamous Cell Carcinomas
Approved drugs for the same conditions: Melanoma · Head and neck cancer · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BL-M08D1" as an intervention, largest first.
- A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaPivotal-lookingNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07818499 · 204 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M08D1; Rituximab and 6 more · For: Diffuse Large B-Cell Lymphoma
Sites: Guangzhou, China; Suzhou, China
- A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid TumorsNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07793825 · 90 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M08D1 · For: Gynecological Tumors; Solid Tumors
Sites: Hangzhou, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07780318 · 60 participants (planned) · Start Sep 11, 2026 · Primary completion Dec 2028
Drug: BL-M08D1 · For: Gastrointestinal Tumors; Solid Tumors
Sites: Beijing, China
- A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07788950 · 30 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M08D1 · For: Head and Neck Squamous Cell Carcinomas; Solid Tumors
Sites: Shanghai, China
- A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid TumorsRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07841925 · 30 participants (planned) · Start Oct 13, 2026 · Primary completion Dec 2028
Drug: BL-M08D1 · For: Melanoma; Solid Tumors
Sites: Beijing, China
- A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid TumorsNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07818486 · 30 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M08D1 · For: Nasopharyngeal Carcinoma (NPC); Solid Tumors
Sites: Chongqing, China; Guangzhou, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06718621 · 22 participants (planned) · Start Feb 12, 2025 · Primary completion Dec 2026
Drug: BL-M08D1 · For: Solid Tumor
Sites: Shanghai, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06718634 · 22 participants (planned) · Start Jan 2, 2025 · Primary completion Jun 2027
Drug: BL-M08D1 · For: Relapsed or Refractory Lymphoid Malignancies
Sites: Harbin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.